Nebivolol Al (Nebivolol)

• Nebivolol is a selective beta‑1 blocker used to manage conditions within the cardiovascular disease spectrum.
• Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension.
• Essential hypertension: helps achieve guideline‑recommended blood‑pressure targets.
• High blood pressure: reduces cardiovascular risk by controlling both systolic and diastolic values.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and myocardial contractility. Concurrently, it stimulates endothelial nitric oxide synthase, promoting nitric‑oxide‑mediated vasodilation, which together produce a reduction in systemic vascular resistance and arterial pressure.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness.
• Nasal congestion or rhinorrhea.
• Bradycardia: heart rate slower than normal.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Symptomatic hypotension with risk of syncope.
• Acute bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, pruritus, or angioedema.
• Hepatic dysfunction or elevated liver enzymes.
• Cardiovascular collapse in the setting of overdose.

Before initiating Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Cardiovascular assessment: monitor heart rate and blood pressure regularly.
• Renal impairment: use with caution and adjust dosing if necessary.
• Hepatic disease: consider reduced clearance and monitor liver function.
• Respiratory conditions: avoid in patients with active asthma or severe COPD.
• Pregnancy and lactation: safety not established; weigh benefits against risks.
• Drug interaction review: assess concomitant medications for additive effects.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: additive bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and severe bradycardia.
• Clonidine abrupt withdrawal: may precipitate rebound hypertension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: potential for enhanced hypotensive effect.
• Diuretics: may increase orthostatic hypotension.
• Antidiabetic agents: beta‑blockade can mask hypoglycaemia symptoms.
• Antidepressants (SSRIs, SNRIs): may affect heart rate variability.
• NSAIDs: can attenuate antihypertensive efficacy.